C2N Diagnostics Secures $10M Investment from Samsung for Brain Health Innovation

• C2N Diagnostics has received a $10 million investment from Samsung to scale its clinical laboratory services and diagnostic solutions in brain health.

• The investment will support the expansion of C2N’s Precivity blood biomarker testing portfolio and next-generation diagnostic assays for Alzheimer’s disease and related dementias.

C2N Diagnostics has announced a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation. The funding will support C2N’s efforts to expand its clinical laboratory services and advanced diagnostic solutions in brain health, particularly in Alzheimer’s disease diagnostics.

Jaywoo Kim, Executive Vice President of Samsung C&T Corporation, stated, “Since Samsung C&T stepped into the life sciences industry by investing in biologics CDMO and biosimilar business, it has contributed to the stabilization of the biopharmaceutical supply chain and better access to high-quality biopharmaceutics. The investment into C2N Diagnostics shows Samsung’s continued dedication to future growth in the Life Science sector by seeking new business opportunities based on intelligent analytics and uniquely special diagnostics technologies.”

The investment aims to accelerate C2N’s biomarker research, expand commercial capabilities, and drive innovation in diagnostic testing. C2N’s PrecivityAD2 blood test recently demonstrated over 90% diagnostic accuracy in a clinical study published in the Journal of the American Medical Association (JAMA). The test helps primary care physicians and memory care specialists diagnose Alzheimer’s disease more effectively.

C2N has processed over 50,000 Precivity analytes and collaborated with more than 150 academic, clinical, and research partners worldwide. The company is now working on expanding its biomarker pipeline with assays targeting tau pathology, Parkinson’s disease, and new technologies to decentralize mass spectrometry testing.

Dr. Joel Braunstein, CEO of C2N, expressed confidence in the partnership, stating, “Samsung’s important investment will allow C2N to further strengthen our capabilities, expand our commercial scale, and innovate next-generation diagnostic tests that can improve patients’ lives.”